Improving cardiopulmonary bypass: heparin-coated circuits.
Heparin-coated circuits have been repeatedly proven to reduce the inflammatory response and foreign surface activation triggered upon initiation of cardiopulmonary bypass (CPB). In recent years, increasing numbers of studies are proving significant reductions in postoperative blood loss and transfusion requirements and improvements in clinical outcomes as a result of heparin-coated circuits. These results are promising steps in our efforts to improve CPB, as our patient population gets older and more complicated.
Division of Cardiothoracic Surgery, Department of Surgery, University of Washington, Seattle, Washington 98195-3166, USA.
Craig
C
Vocelka
Gina
G
Lindley
D000925:Anticoagulants / Q000008:administration & dosage* / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects; D001779:Blood Coagulation Factors / Q000187:drug effects; D002315:Cardiopulmonary Bypass / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods; D020099:Coated Materials, Biocompatible; D016503:Drug Delivery Systems; D006493:Heparin / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007249:Inflammation / Q000517:prevention & control*; D019106:Postoperative Hemorrhage / Q000517:prevention & control; D012307:Risk Factors
D000925:Anticoagulants; D001779:Blood Coagulation Factors; D020099:Coated Materials, Biocompatible; D006493:Heparin